赛伦斯治疗
SLN
8.68
-0.67
-7.17%
赛伦斯治疗
US · SLN
#3615 按市值排名
8.68
-0.67
-7.17%
实时 - 追踪5344个代码 - 心跳于82秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了11.1个百分点。
机构持股
- 机构持股比例
- 38.68% -11.14pp
- 机构数量
- 89 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund17.01%
Individual/Insider14.84%
VC/PE Fund12.98%
Mutual Fund5.96%
Private Company1.66%
Public Company1.07%
Other46.47%
主要股东 截至 2026-08-12
Richard Griffiths
7.97% · 4.80M 股
Robert Keith
6.81% · 4.10M 股
TCG Crossover Management, LLC
5.04% · 3.03M 股
Artal Group S.A.
4.82% · 2.90M 股
Redmile Group, LLC
3.60% · 2.16M 股
Nantahala Capital Management, LLC
2.24% · 1.35M 股
Citadel Advisors LLC
2.21% · 1.33M 股
Nextech Invest Ltd.
1.58% · 952.40K 股
Millennium Management LLC
1.51% · 909.28K 股
Tetragon Partners UK LLP
1.27% · 764.26K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 36次买入 · 2次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Richard Griffiths | -- | 7.97% |
| Craig Tooman | Chief Executive Officer | 0.02% |
| James Ede-Golightly | Independent Non-Executive Director | 0.01% |
| Michael Davidson | Independent Non-Executive Director | 0.01% |
| Steven Romano | Chief Medical Officer and Head of Research & Development | 0.01% |
| David Lemus | Independent Non-Executive Director | 0.00% |
| Rhonda Hellums | Chief Financial Officer | 0.00% |
| Timothy McInerney | Director | -- |
| Ian Ross | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-07-05 | Richard Griffiths | -- | Private Disposition | -1,544,374 | -- |
| 2026-01-01 | Timothy McInerney | Director | Other Derivative Acquisition | +90,000 | $2.05 |
| 2026-01-01 | David Lemus | Independent Non-Executive Director | Other Derivative Acquisition | +90,000 | $2.05 |
| 2026-01-01 | James Ede-Golightly | Independent Non-Executive Director | Other Derivative Acquisition | +90,000 | $2.05 |
| 2026-01-01 | Steven Romano | Chief Medical Officer and Head of Research & Development | Other Derivative Acquisition | +300,000 | $2.05 |
| 2026-01-01 | Rhonda Hellums | Chief Financial Officer | Other Derivative Acquisition | +375,000 | $2.05 |
| 2025-12-21 | James Ede-Golightly | Independent Non-Executive Director | Other Derivative Acquisition | +90,000 | $2.15 |
| 2025-12-17 | Ian Ross | -- | Other Derivative Acquisition | +900,000 | $2.08 |
| 2025-12-13 | James Ede-Golightly | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2025-10-26 | Richard Griffiths | -- | Open Market Derivative Acquisiti | +22,000 | $5.45–7.75 |
| 2025-10-26 | Richard Griffiths | -- | Other Derivative Acquisition | +2,000 | $7.75 |
| 2025-08-02 | Richard Griffiths | -- | Open Market Derivative Dispositi | -20,000 | $5.45 |
| 2025-07-31 | Richard Griffiths | -- | Private Acquisition | +18,376 | -- |
| 2025-07-29 | Richard Griffiths | -- | Private Acquisition | +23,482 | -- |
| 2025-07-10 | Richard Griffiths | -- | Private Acquisition | +71,293 | -- |
| 2025-07-08 | Richard Griffiths | -- | Private Acquisition | +62,457 | -- |
| 2025-06-26 | Richard Griffiths | -- | Private Acquisition | +110,474 | -- |
| 2025-06-23 | Richard Griffiths | -- | Private Acquisition | +82,606 | -- |
| 2025-06-17 | Richard Griffiths | -- | Open Market Acquisition | +70,448 | $5.29 |
| 2025-06-11 | Richard Griffiths | -- | Private Acquisition | +39,305 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
赛伦斯治疗 讨论区 0 条评论